Clinical trials: Skin Absorption
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
A Study to Assess the Mass Balance Recovery (Absorption, Distribution, Metabolism and Excretion) of [14C]CCX168 in Healthy Participants
The primary objective of this study is to perform mass balance following a single oral dose of [14C]CCX168 in healthy adult male participants.
- Trial name
- NCT06004960
- Testing
- [14C]CCX168
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Amgen
Onychomycosis
Pharmacokinetics and Safety Study of ME1111 in Moderate to Severe Onychomycosis Patients
This study is Randomized, Double-Blind, Vehicle-Controlled, Multiple-Dose Study. The purpose is to determine the safety, tolerability, systemic exposure and pharmacokinetics of ME1111 after repeated daily topical application of…
- Trial name
- NCT01841996
- Testing
- ME1111 solution, Vehicle Solution
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Health Adult Subjects
An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects
The goal of this clinical trial is to evaluate the safety, local tolerability, and pharmacokinetic (PK) profile of YR001 Topical Ointment in healthy Chinese participants.
- Trial name
- NCT07673458
- Testing
- PA032, Vehicle Ointment
- Where
- China
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Acne
Absorption and Systematic Pharmacokinetics of IDP-121 Lotion in Subjects With Acne Vulgaris
Open-Label study designed to assess the safety and plasma PK of tretinoin and relevant metabolites after topical dermal application of IDP-121 lotion.
- Trial name
- NCT02849860
- Testing
- IDP-121 Lotion
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Bausch Health Americas, Inc.
Mild to Moderate Atopic Dermatitis
Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema
Atopic dermatitis (AD) is a chronic or chronic recurring inflammatory skin disorder. Patients suffer from eczema and often severe pruritus on the affected skin, as well as from frequent complications and secondary infections.
- Trial name
- NCT02079688
- Testing
- SB011, 2 % (Water/Oil/Water) emulsion of hgd40, Multiple W/O/W formulation, active ingredient-free vehicle
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Sterna Biologicals GmbH & Co. KG
Actinic Keratoses
Pharmacokinetic Study to Evaluate the Extent of Systemic Absorption of PEP005
The purpose of this study is to determine the extent of systemic absorption of PEP005 when applied topically for the treatment of actinic keratoses.
- Trial name
- NCT00544258
- Testing
- PEP005
- Where
- Australia
- Volunteers
- 8 people
- Sponsor
- Peplin
Psoriasis
A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis
This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants…
- Trial name
- NCT03987763
- Testing
- IDP-122 Lotion
- Where
- 9 sites in United States, Dominican Republic and 1 more
- Volunteers
- 45 people
- Sponsor
- Bausch Health Americas, Inc.
Acne
Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream
The Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison with Tazorac Cream.
- Trial name
- NCT02849873
- Testing
- IDP-123 Lotion, Tazorac Cream
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Bausch Health Americas, Inc.
Hereditary Angioedema
Study to Determine How BCX4161 is Metabolized and Eliminated by the Body
The purpose of the study is to assess the extent that radioactive dose of BCX4161 taken by mouth ends up in the urine, feces and expired air.
- Trial name
- NCT02218294
- Testing
- BCX4161
- Where
- United Kingdom
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- BioCryst Pharmaceuticals
Chronic Small Plaque Psoriasis
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
The primary objective of the study is to evaluate the safety and tolerability of 50, 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with plaque psoriasis
- Trial name
- NCT00396422
- Testing
- RWJ-445380
- Volunteers
- 60 people
- Sponsor
- Alza Corporation, DE, USA
Psoriasis
DFD06 Cream vs Clobetasol Propionate Cream, 0.05% Hypothalamic- Pituitary-Adrenal (HPA) Axis Suppression Study in Patients With Moderate to Severe Plaque Psoriasis
The purpose of this study is to evaluate the potential of DFD06 cream to suppress the HPA (hypothalamic-pituitary-adrenal) axis as compared to clobetasol propionate cream, 0.05% cream when applied twice daily for 15 days.
- Trial name
- HPA axis (NCT02131324)
- Testing
- DFD06 Cream, Clobetasol Propionate Cream 0.05%
- Where
- 15 sites in United States
- Volunteers
- 50 people
- Sponsor
- Promius Pharma, LLC
Onychomycosis
Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)
The purpose of the study is to determine the absorption, systemic pharmacokinetics and accumulation in the nail of AN2690 during a 28 day period of daily application of a 7.5% solution of AN2690 to all 10 toenails of up to 25…
- Trial name
- NCT00680160
- Testing
- AN2690
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Pfizer